Sumitomo Chemical India Limited declared a dividend of ₹1.30 per equity share and approved key leadership transitions at its 26th Annual General Meeting (AGM) held on July 27, 2026. The meeting, conducted via Video Conferencing (VC) and Other Audio Visual Means (OAVM), also sanctioned material related-party transactions with Sumitomo Chemical Company, Limited for the financial year 2026-27.

The AGM commenced at 02:30 P.M. with 65 members present, satisfying the quorum requirements under the Companies Act, 2013 and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Dr. Mukul G. Asher, Chairman of the Board of Directors, chaired the proceedings. All Directors, Statutory Auditors, Secretarial Auditors, and the Scrutinizer attended the meeting. The Company Secretary & Compliance Officer, Deepika Trivedi, submitted the proceedings to BSE Limited and The National Stock Exchange of India in compliance with Regulation 30, Part – A of Schedule – III of the SEBI (LODR) Regulations, 2015.

Key Resolutions Passed

Shareholders approved ordinary and special resolutions covering financial statements, dividends, and board appointments. The detailed voting outcomes are summarized below:

Leadership Transitions

The board restructuring involves significant role changes effective from late August and early September 2026. Dr. Suresh Ramachandran, currently Deputy Managing Director, will be promoted to Managing Director starting September 1, 2026. Concurrently, Mr. Chetan Shah, whose tenure as Managing Director concludes on August 31, 2026, will transition to the role of Non-Executive Non-Independent Director from September 1, 2026. Shareholders also approved the payment of advisory fees, commission, and sitting fees to Mr. Shah for one year from his new appointment date.

Two new Independent Directors were appointed to strengthen the board’s oversight capabilities. Mr. N. Sivaraman was reappointed for a second term of three years, effective September 1, 2026. Mr. Anand Mohan Tiwari was appointed for a term of two years, effective August 31, 2026. Dr. Suresh Ramachandran was also re-appointed as a Director after retiring by rotation.

Related Party Transactions and Compliance

The AGM approved material related-party transactions entered into and proposed to be entered into with Sumitomo Chemical Company, Limited during the Financial Year 2026-27. This approval ensures continued operational synergy while maintaining regulatory compliance. The remuneration of M/s. GMVP & Associates LLP, the Cost Auditors, was ratified by shareholders. Mr. Kamalax G. Saraf was appointed as Scrutinizer, with Mr. Mandar K. Saraf as alternate, to supervise the e-voting process. The final voting results will be disseminated to exchanges and published on the company’s website.

Sumitomo Chemical India Limited reported a 20.4% year-on-year increase in standalone net profit to ₹2,165.29 million for the quarter ended June 30, 2026 (Q1FY26), primarily driven by a one-time insurance claim. The agro-chemicals company’s consolidated net profit attributable to owners of the holding company rose 20.5% to ₹2,148.30 million, while revenue from operations grew marginally by 0.6% to ₹10,540.75 million on a standalone basis and remained flat at ₹10,633.46 million on a consolidated basis compared to the prior year period.

The Board of Directors approved the unaudited financial statements on July 27, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by B S R & Co. LLP, the statutory auditors. The filing includes both standalone and consolidated financial results for the quarter, prepared in accordance with Indian Accounting Standards (Ind AS).

Key Financial Highlights

The following table presents the standalone and consolidated financial performance for Q1FY26:

On an operational efficiency front, consolidated EBITDA improved to ₹2.3 billion from ₹2.2 billion in the same quarter last year, with the EBITDA margin expanding to 22% from 20.74% year-on-year. Other income contributed ₹472.84 million to the consolidated total, up from ₹387.86 million in the prior year period. Total comprehensive income for the group stood at ₹2,135.28 million.

What the Numbers Show

The profit growth was significantly boosted by exceptional items rather than core operational expansion. The company recorded a ₹268.96 million gain from an insurance claim for business interruption due to a fire incident at its Bhavnagar plant during FY23. Excluding this one-time gain, the core operational profit before tax was ₹2,643.65 million (standalone), reflecting steady underlying performance. In contrast, the prior year saw a ₹151.86 million exceptional charge related to new labour codes, highlighting the volatility from regulatory and non-operational factors.

Regulatory risks remain a key focus for the agro-chemicals segment. A Central Government notification issued in October 2022 mandates that Glyphosate, a critical product, be used only through Pest Control Operators. Industry petitions challenging this notification are pending before the Delhi High Court, with the government stating implementation will be stayed until disposal. The company operates in a single reportable segment, making it susceptible to these regulatory shifts and climatic variations affecting demand. The consolidated results include two subsidiaries: Barrix Agro Sciences Private Limited and Excel Crop Care (Africa) Limited, which is under liquidation.